

Bioarray & IVFSpain present clinical outcome of PGS by NGS: 64 babies since 2015

Bioarray genetic lab and IVF-Spain fertility clinic present at ESHRE meeting (Helsinki, July 3-6) outcome of PGS using NGS: 64 babies and 53 ongoing pregnancies

ALICANTE, SPAIN, June 29, 2016 /EINPresswire.com/ -- Bioarray, S.L., IVF SPAIN S.L. and iGLS will present clinical outcomes of IVF treatments with [PGS](#) by NGS, after two years providing this genetic test as part of a cooperation supported in a framework agreement. The upcoming Annual Meeting of [ESHRE](#), European Society of Human Reproduction and Embryology (Helsinki, 3 to 6 July) will be the chosen context for this release, being a key event for the fertility community in Europe and worldwide.

PGS, Preimplantation Genetic Screening, is a genetic test that analyses biopsied cells from embryos produced by in vitro fertilization (IVF) techniques. PGS determines whether the embryos are chromosomally normal (euploid) or not, thus giving the chance to transfer chromosomally normal embryos that are more apt to successfully implant and develop into a pregnancy.


In 2014 Bioarray developed, validated and released PGS using NGS, Next Generation Sequencing, currently the most advanced molecular technology for the study of human genome. Since then, the alliance between Bioarray genetic lab and IVF-Spain fertility clinic has provided PGS to more than hundred European couples, with the first born baby

screened by this method in September 2015. To date an overall of 64 born babies and 53 ongoing

BA BIOARRAY
Genetic Diagnosis



Blastocyst biopsy for PGS



Vanessa Penacho PhD, Bioarray's R&D

pregnancies have been achieved.

Moreover, this alliance has also provided PGD, Preimplantation Genetic Diagnosis by NGS for a number of couples carrying a single-gene disorder, who had their embryos checked to prevent the disease being passed to their children. In this regards Bioarray integrated PGD setup + PGD + PGS in a single fast robust NGS workflow, providing unparalleled benefits to patients.

About Bioarray and IVF Spain

Bioarray (<http://www.bioarray.es/en>) is a Spanish biotech company specialized in genetic diagnosis using cutting-edge molecular biology technologies, focused on medical and genomic research areas. Bioarray's medical genetic tests are mainly intended for pediatric, reproductive and oncology areas. Bioarray specializes in DNA microarrays (aCGH) and Next Generation Sequencing, with a highly proficient bioinformatics team, a fundamental part of genetic analysis.

IVF Spain (<http://www.ivf-spain.com/>) is a leading Spanish fertility clinic located in Alicante. It counts on a highly qualified and experienced international team of more than 35 professionals. The medical team is led by Dr Jon Aizpurua, an internationally renowned physician in the field of assisted reproduction. IVF Spain focuses on providing a personalised treatment and service in more than 6 languages. IVF Spain, through its analysis laboratory and R+D department, iGLS, is committed to being at the forefront of assisted reproduction research, constantly assessing and using innovation to ensure our patients receive the best possible treatment.

Luis Valino
Bioarray, S.L.
+34966682500
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.